Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 9/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958732 | 0.96 | CARM1 (0.54) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL30754913 | 0.89 | CARM1 (0.62) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL21958107 | 0.88 | CARM1 (0.51) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL102306 | 0.80 | CARM1 (0.58) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL2297042 | 0.80 | CARM1 (0.58) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL14261323 | 0.79 | CARM1 (0.48) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL8633784 | 0.78 | CARM1 (0.57) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL4961595 | 0.78 | SLC6A2 (0.46) | CARM1PRMT6SIGMAR1TMEM97NAAA | |
| SCHEMBL22306741 | 0.77 | CARM1 (0.42) | CARM1PRMT6DRD4SIGMAR1DRD1 | |
| SCHEMBL24168671 | 0.76 | SLC6A4 (0.59) | CARM1PRMT6DRD4SIGMAR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | CARM1 1572/4885PRMT6 2833/4885DRD4 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.